257 related articles for article (PubMed ID: 28595620)
1. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I.
Nestrasil I; Shapiro E; Svatkova A; Dickson P; Chen A; Wakumoto A; Ahmed A; Stehel E; McNeil S; Gravance C; Maher E
Am J Med Genet A; 2017 Mar; 173(3):780-783. PubMed ID: 28211988
[TBL] [Abstract][Full Text] [Related]
4. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs.
Passage MB; Krieger AW; Peinovich MC; Lester T; Le SQ; Dickson PI; Kakkis ED
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1(Suppl 1):S253-8. PubMed ID: 19562502
[TBL] [Abstract][Full Text] [Related]
6. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
10. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Ou L; Przybilla MJ; Koniar B; Whitley CB
Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
[TBL] [Abstract][Full Text] [Related]
14. Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients.
Vera M; Le S; Kan SH; Garban H; Naylor D; Mlikotic A; Kaitila I; Harmatz P; Chen A; Dickson P
Pediatr Res; 2013 Dec; 74(6):712-20. PubMed ID: 24002329
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
[TBL] [Abstract][Full Text] [Related]
16. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
[TBL] [Abstract][Full Text] [Related]
17. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
[TBL] [Abstract][Full Text] [Related]
20. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]